About US
Contact us
-
A&C American Chemicals Received EXCiPACT Certification as Pharmaceutical Excipient SupplierEXCiPACTasbl is delighted to announce that A&C American Chemicals of Montreal, Quebec, Canada has received an EXCiPACT Certificate from SGS, one of EXCIPACT’s internationally recognised Certificat2014/2/24
-
US FDA grants priority review for expanded use of Navidea's LymphoseekThe US Food and Drug Administration (FDA) has accepted Navidea Biopharmaceuticals' supplemental new drug application (sNDA) and granted a priority review for the expanded use of Lymphoseek (technetium2014/2/21
-
Cellectis and Servier partner to develop new products targeting solid tumoursAllogeneic CAR T-cell therapies provider Cellectis has entered into a strategic collaboration agreement with French pharmaceutical research firm Servier for the development and commercialisation of ne2014/2/21
-
Chelsea receives FDA accelerated approval for Northera for treatment of patients with symptomatic NOHChelsea Therapeutics has received approval from the US Food and Drug Administration (FDA) to use Northera capsules (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH)2014/2/20
-
FDA rejects expanded use of Bayer and Janssen's anti-clot drug XareltoThe Food and Drug Administration has rejected the supplemental new drug applications seeking the use of Bayer and Janssen's anti-clotting drug Xarelto (rivaroxaban) for prevention of heart attacks or2014/2/20
-
BioMarin's Vimizim gets FDA approval for treatment of Morquio A SyndromeUS-based BioMarin Pharmaceutical has received approval from the US Food and Drug Administration (FDA) to use its Vimizim (elosulfase alfa) for treatment of patients with mucopolysaccharidosis type IVA2014/2/19
-
Samyang to distribute BMG Pharma's GelX in South KoreaItaly-based BMG Pharma has signed an exclusive distribution agreement with Samyang Biopharmaceutical for its novel mucositis management product, GelX. As part of the deal, Samyang receives the rights2014/2/19
-
Hepatitis B Vaccine Market to Experience Modest Growth Despite Upcoming Product LaunchesThe global hepatitis B virus (HBV) vaccine market value will experience modest growth over the coming years, climbing from approximately $959.9 million in 2012 to $1.19 billion by 2022, at a Compound2014/2/18
-
BioMarin's Vimizim gets FDA approval for treatment of Morquio A SyndromeUS-based BioMarin Pharmaceutical has received approval from the US Food and Drug Administration (FDA) to use its Vimizim (elosulfase alfa) for treatment of patients with mucopolysaccharidosis type IVA2014/2/18
-
FDA Grants Accelerated Approval to ibrutinib for the Treatment of Patients with CLLOn 12 February 2014, FDA granted accelerated approval to ibrutinib (IMBRUVICA, Pharmacyclics, Inc.) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one2014/2/17